Cullinan Therapeutics(CGEM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CGEM Cullinan Therapeutics

盘后交易 09-16 18:07:43 EDT

20.63

+0.09

+0.44%

盘后20.93

+0.30+1.45%

16:14 EDT

最高20.84	最低20.20	成交量82.57万
今开20.50	昨收20.54	日振幅3.14%
总市值13.28亿	流通市值9.92亿	总股本6,435万
成交额1,698万	换手率1.72%	流通股本4,808万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CGEM","market":"US","secType":"STK","nameCN":"Cullinan Therapeutics","latestPrice":20.63,"timestamp":1789588800000,"preClose":20.54,"halted":0,"volume":825671,"hourTrading":{"tag":"盘后","latestPrice":20.93,"preClose":20.63,"latestTime":"16:14 EDT","volume":30968,"amount":638871.295496,"timestamp":1789589665370,"change":0.3,"changeRate":0.014542,"amplitude":0.014542},"delay":0,"changeRate":0.00438169425511197,"floatShares":48082800,"shares":64354694,"eps":-3.468035,"marketStatus":"盘后交易","change":0.09,"latestTime":"09-16 18:07:43 EDT","open":20.5,"high":20.84,"low":20.195,"amount":16983706,"amplitude":0.031402,"askPrice":21.03,"askSize":95,"bidPrice":20.57,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-3.468035,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"listingDate":1610082000000,"exchange":"NASDAQ","adjPreClose":20.54,"preHourTrading":{"tag":"盘前","latestPrice":19.6,"preClose":20.54,"latestTime":"08:18 EDT","volume":1687,"amount":34305.065710999996,"timestamp":1789561098944,"change":-0.94,"changeRate":-0.045764,"amplitude":0.093963},"postHourTrading":{"tag":"盘后","latestPrice":20.93,"preClose":20.63,"latestTime":"16:14 EDT","volume":30968,"amount":638871.295496,"timestamp":1789589665370,"change":0.3,"changeRate":0.014542,"amplitude":0.014542},"volumeRatio":0.730129,"impliedVol":1.4523,"impliedVolPercentile":0.8446},"requestUrl":"/m/hq/s/CGEM","defaultTab":"news","newsList":[{"id":"1189364454","title":"Zipalertinib联合化疗在Rezilient3 III期试验中显著提升一线EGFR外显子20插入突变非小细胞肺癌患者无进展生存期，中位获益达6个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1189364454","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189364454?lang=zh_cn&edition=full","pubTime":"2026-09-14 07:16","pubTimestamp":1789341368,"startTime":"0","endTime":"0","summary":"在针对一线EGFR外显子20插入突变非小细胞肺癌患者的Rezilient3 III期临床试验中，zipalertinib联合化疗方案展现出令人瞩目的疗效——中位无进展生存期获得了长达6个月的显著改善。这一数据为这一特定肺癌亚型患者群体带来了新的治疗曙光，值得临床界广泛关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165028117","title":"Cullinan Therapeutics旗下Zipalertinib联合化疗在Rezilient3三期试验中达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1165028117","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165028117?lang=zh_cn&edition=full","pubTime":"2026-08-13 18:08","pubTimestamp":1786615703,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics宣布，其研发药物Zipalertinib与化疗联合疗法，在代号为Rezilient3的III期临床试验中，成功达到了预设的主要终点。（注：根据原文内容，该句为独立核心信息，无附加段落分隔。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150020764","title":"Cullinan Therapeutics 与 Taiho Oncology 及 Taiho Pharmaceutical 联合推进 Zipalertinib 组合疗法在美国的监管审批","url":"https://stock-news.laohu8.com/highlight/detail?id=1150020764","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150020764?lang=zh_cn&edition=full","pubTime":"2026-08-13 18:07","pubTimestamp":1786615622,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics 携手 Taiho Oncology 与 Taiho Pharmaceutical，共同启动了一项关键举措——为 Zipalertinib 联合疗法争取美国监管机构的批准。这一战略合作标志着三方将合力推动该创新药物组合在美国市场的上市进程。Cullinan Therapeutics 作为主导方，正与 Taiho Oncology 及 Taiho Pharmaceutical 紧密协作，旨在加速这一潜在疗法的审批流程，以满足未竟的医疗需求。Zipalertinib 的联合应用有望为患者带来新的治疗选择，而此次合作也凸显了各方在肿瘤学领域的深厚布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165396510","title":"Zipalertinib显著提升无进展生存期，安全性可控——Cullinan Therapeutics迎重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1165396510","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165396510?lang=zh_cn&edition=full","pubTime":"2026-08-13 18:05","pubTimestamp":1786615513,"startTime":"0","endTime":"0","summary":"在Cullinan Therapeutics的研发管线中，Zipalertinib治疗组展现出令人瞩目的成果：无进展生存期获得显著改善，同时安全性表现可控。这一进展，无疑为肿瘤治疗领域注入了一剂强心针。试验数据表明，接受Zipalertinib治疗的患者，其疾病进展时间被有效延长，且不良反应的严重程度与发生率均维持在可管理的范围内。所以，这不仅是数字上的提升，更是对治疗策略的实质性优化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130085492","title":"Cullinan Therapeutics 第二季度运营亏损5725.4万美元，与市场预期基本持平","url":"https://stock-news.laohu8.com/highlight/detail?id=1130085492","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130085492?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:18","pubTimestamp":1786015103,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics 于8月6日公布了第二季度财务数据。据报告，该公司第二季度运营收入为负5725.4万美元，而市场普遍预期（IBES估算）为负5710万美元，两者差距不大。此外，公司第二季度净收入为负5370.4万美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131205168","title":"Cullinan Therapeutics 二期临床研究将引入剂量优化与推荐剂量单臂队列","url":"https://stock-news.laohu8.com/highlight/detail?id=1131205168","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131205168?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:02","pubTimestamp":1785236549,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics 宣布，其即将开展的二期研究将纳入剂量优化环节，并设立推荐剂量下的单臂队列。这一设计旨在进一步精准评估候选药物的疗效与安全性，为后续临床开发奠定更坚实的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132927994","title":"Cullinan Therapeutics 宣布 CLN-049 与 FDA 的 I 期结束会议取得积极成果，计划推进至潜在注册性 II 期 AML 研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1132927994","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132927994?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:01","pubTimestamp":1785236472,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics 正式对外披露，其针对候选药物 CLN-049 与美国食品药品监督管理局（FDA）召开的 I 期结束会议已取得积极反馈。基于这一关键进展，公司决定将该项目推进至一项具有潜在注册意义的 II 期临床研究，针对适应症为急性髓系白血病（AML）。这一举措标志着该药物的开发进程迈入关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136947988","title":"Cullinan Therapeutics：预计下季度公布CLN-978针对类风湿关节炎的多剂量数据，第四季度公布系统性红斑狼疮数据，并于年底前公布velinotamig额外数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1136947988","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136947988?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:33","pubTimestamp":1781091196,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics宣布，其研发管线中的两项关键资产即将迎来新的临床数据更新。公司预计，针对自身免疫性疾病候选药物CLN-978，将在下一季度获得用于治疗类风湿关节炎（RA）的额外多剂量数据，而针对系统性红斑狼疮（SLE）的同类数据则计划于今年第四季度公布。此外，另一款在研药物velinotamig的额外临床数据也有望在年底前获得。这些数据节点对于评估药物的安全性和有效性至关重要，或将影响公司未来的研发决策与合作伙伴的洽谈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140275471","title":"Cullinan Therapeutics公布CLN-978 EULAR数据：展现免疫重置潜力，在SLE和RA中均观察到缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1140275471","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140275471?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:32","pubTimestamp":1781091176,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics公司公布了其候选药物CLN-978（一种CD19 T细胞衔接器）在EULAR大会上展示的数据。数据显示，该药物在系统性红斑狼疮和类风湿关节炎患者中均表现出诱导免疫重置的潜力，其中包含了疾病缓解的案例。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152070634","title":"Cullinan Therapeutics公布靶向CD19和BCMA的T细胞衔接器项目在自身免疫性疾病中的新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070634","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152070634?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:31","pubTimestamp":1781091106,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics公布了其针对自身免疫性疾病研发的、靶向CD19和BCMA的T细胞衔接器项目组合的最新临床数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148698852","title":"Cullinan Therapeutics 旗下CLN-978在单靶点剂量高达30微克及初步多剂量方案中均展现良好安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=1148698852","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148698852?lang=zh_cn&edition=full","pubTime":"2026-06-06 17:17","pubTimestamp":1780737437,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics公司研发的CLN-978，其安全性数据令人鼓舞。不仅在单靶点剂量高达30微克的水平上表现出良好的耐受性，初步的多剂量给药方案也显示出积极的安全特征。这一进展为后续的临床开发奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199184329","title":"Cullinan Therapeutics旗下新型Flt3xCD3 T细胞衔接器CLN-049获FDA孤儿药资格认定，用于治疗复发/难治性急性髓系白血病","url":"https://stock-news.laohu8.com/highlight/detail?id=1199184329","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199184329?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:02","pubTimestamp":1779188575,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics公司宣布，其研发的新型Flt3xCD3 T细胞衔接器CLN-049，已获得美国食品药品监督管理局（FDA）授予的孤儿药资格认定，适应症为复发或难治性急性髓系白血病（AML）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128910671","title":"Cullinan Therapeutics提交销售协议招股书 拟募资高达2亿美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1128910671","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128910671?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:55","pubTimestamp":1777377317,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics公司近日披露，其提交的销售协议招股说明书已获通过，公司将通过公开发行普通股募集最高2亿美元资金。\n此次融资计划将为公司后续研发管线推进提供重要资金支持。根据备案文件显示，该销售协议允许公司适时向市场分批发行普通股股份。\n生物科技企业通常通过二级市场融资来加速临床试验及商业化进程。Cullinan Therapeutics此次募资规模显示出市场对其研发前景的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104280883","title":"Cullinan Therapeutics 公司PDUFA目标审评日期定为2027年2月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=1104280883","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104280883?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:11","pubTimestamp":1777374672,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics Inc. 宣布，其药物审评的关键时间节点——处方药用户费用法案（PDUFA）目标行动日期已确定为2027年2月27日。这一日期标志着美国食品药品监督管理局（FDA）完成对该公司新药申请审查的最终期限。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196727944","title":"美国FDA受理Zipalertinib新药申请 用于治疗EGFR外显子20插入突变局部晚期或转移性非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1196727944","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196727944?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:09","pubTimestamp":1777374546,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式受理了Zipalertinib的新药上市申请，该药物针对携带EGFR外显子20插入突变的局部晚期或转移性非小细胞肺癌患者。这一重要进展标志着靶向治疗在该特定肺癌亚型领域迈出关键一步。\nZipalertinib作为一种创新疗法，专注于解决现有治疗方案有限的医疗需求。临床数据显示，该药物在控制肿瘤生长和改善患者预后方面展现出显著潜力。此次新药申请获FDA受理，为罕见突变肺癌患者带来了新的治疗希望。\n监管部门将对提交的临床研究数据进行全面审评，以评估药物的安全性与有效性。若最终获批，Zipalertinib有望成为该类特定基因突变肺癌患者的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518209158","title":"Cullinan Therapeutics, Inc.盘中异动 快速跳水5.17%报8.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518209158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518209158?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:24","pubTimestamp":1741631062,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时24分，Cullinan Therapeutics, Inc.股票出现波动，股价大幅跳水5.17%。截至发稿，该股报8.26美元/股，成交量27.8959万股，换手率0.48%，振幅4.42%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为5992.88%、3846.69%、1004.73%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、59.34%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102242296406faa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102242296406faa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517543010","title":"Cullinan Therapeutics, Inc.2024财年实现净利润-1.67亿美元，同比减少9.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517543010","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517543010?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363238,"startTime":"0","endTime":"0","summary":"3月8日，Cullinan Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.67亿美元，同比减少9.15%；其中营业收入为0.00美元，每股基本收益为-3.11美元。从资产负债表来看，Cullinan Therapeutics, Inc.总负债32.10百万美元，其中短期债务1.30百万美元，资产负债比为0.20，流动比率为0.14。机构评级：截至2025年3月8日，当前有9家机构对Cullinan Therapeutics, Inc.目标价做出预测，其中目标均价为32.11美元，其中最低目标价为29.00美元，最高目标价为36.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000048a2647e67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000048a2647e67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CGEM","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516668196","title":"Cullinan Therapeutics, Inc.盘中异动 急速下跌5.18%报8.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668196","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516668196?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:18","pubTimestamp":1741033097,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时18分，Cullinan Therapeutics, Inc.股票出现波动，股价急速下挫5.18%。截至发稿，该股报8.05美元/股，成交量26.88万股，换手率0.46%，振幅6.54%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4598.52%、213.15%、183.16%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041817989a5cd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041817989a5cd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198439624","title":"Cullinan Therapeutics 2024年第四季度GAAP每股收益$(0.73)优于预期$(0.76)","url":"https://stock-news.laohu8.com/highlight/detail?id=1198439624","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198439624?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:28","pubTimestamp":1740659337,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics(CGEM)（纳斯达克股票代码：CGEM）报告称季度每股亏损$(0.73)，优于分析师一致预期的$(0.76)，超出3.95%。以上内容来自Benzinga Earnings专栏，原文如下：$Cullinan Therapeutics(CGEM)$ (NASDAQ:CGEM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 3.95 percent. ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cullinan Therapeutics 2024年第四季度GAAP每股收益$(0.73)优于预期$(0.76)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508141755","title":"Cullinan Therapeutics, Inc.盘中异动 大幅跳水5.11%报10.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508141755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508141755?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:46","pubTimestamp":1738593987,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时46分，Cullinan Therapeutics, Inc.股票出现异动，股价快速跳水5.11%。截至发稿，该股报10.02美元/股，成交量6649股，换手率0.01%，振幅2.51%。Cullinan Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.41%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Invivyd, Inc.涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为413.54%、349.94%、203.60%，振幅较大的相关个股有Hcw Biologics Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Invivyd, Inc.，振幅分别为82.67%、50.76%、35.62%。Cullinan Therapeutics, Inc.公司简介：Cullinan Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203224627abc10aef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203224627abc10aef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CGEM","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cullinantherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.053},{"period":"1month","weight":0.0098},{"period":"3month","weight":0.4224},{"period":"6month","weight":0.5703},{"period":"1year","weight":2.2346},{"period":"ytd","weight":0.9845}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":-0.0244},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.1479},{"period":"1year","weight":0.146},{"period":"ytd","weight":0.1107}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cullinan Therapeutics, Inc.于2016年9月在特拉华州注册成立。该公司是一家生物制药公司，专注于为癌症患者开发具有转化潜力的肿瘤靶向治疗和免疫肿瘤治疗的多样化渠道。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.097052},{"month":2,"riseRate":0.666667,"avgChangeRate":0.069507},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.100308},{"month":4,"riseRate":0.333333,"avgChangeRate":0.044053},{"month":5,"riseRate":0.666667,"avgChangeRate":0.039338},{"month":6,"riseRate":0.5,"avgChangeRate":-0.027852},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004001},{"month":8,"riseRate":0.5,"avgChangeRate":0.087786},{"month":9,"riseRate":0,"avgChangeRate":-0.133925},{"month":10,"riseRate":0.6,"avgChangeRate":0.085935},{"month":11,"riseRate":0.2,"avgChangeRate":-0.037651},{"month":12,"riseRate":0.2,"avgChangeRate":-0.046792}],"exchange":"NASDAQ","name":"Cullinan Therapeutics","nameEN":"Cullinan Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cullinan Therapeutics(CGEM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cullinan Therapeutics(CGEM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cullinan Therapeutics,CGEM,Cullinan Therapeutics股票,Cullinan Therapeutics股票老虎,Cullinan Therapeutics股票老虎国际,Cullinan Therapeutics行情,Cullinan Therapeutics股票行情,Cullinan Therapeutics股价,Cullinan Therapeutics股市,Cullinan Therapeutics股票价格,Cullinan Therapeutics股票交易,Cullinan Therapeutics股票购买,Cullinan Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cullinan Therapeutics(CGEM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cullinan Therapeutics(CGEM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}